# A Study of MRG002 in Patients with HER2-Positive Advanced Solid Tumors and Locally Advanced or Metastatic Gastric/Gastroesophageal Junction (GEJ) Cancer

Source: https://onco.cc/trials/nct04492488/  
OnCo record `nct04492488` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of MRG002 in gastric & gastro-oesophageal junction cancer, run by Shanghai Miracogen Inc., active and no longer recruiting.

## Summary

A Study of MRG002 in Patients with HER2-Positive Advanced Solid Tumors and Locally Advanced or Metastatic Gastric/Gastroesophageal Junction (GEJ) Cancer is a phase 1/2 interventional study registered as NCT04492488 by Shanghai Miracogen Inc., with 129 participants enrolled, started 2021-05-24 and due to reach its primary completion in 2022-10-18. Interventions recorded: MRG002.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04492488
- Phase: 1/2
- Setting: An Open-Label, Multi-center Phase I/II Dose Escalation and Expansion Study to Assess the Safety, Efficacy and Pharmacokinetics of MRG002 in Patients with HER2-Positive Advanced Solid Tumors and Locally Advanced or Metastatic Gastric/Gastroesophageal Junction (GEJ) Cancer
- Sponsor: Shanghai Miracogen Inc.
- Enrolled: 129

## Sources

- ClinicalTrials.gov NCT04492488: https://clinicaltrials.gov/study/NCT04492488

## Connected records

- cancers: [Gastric & gastro-oesophageal junction cancer](https://onco.cc/cancers/gastric/)
- drugs: [MRG002](https://onco.cc/drugs/mrg002/)

---
JSON: https://onco.cc/api/v1/entities/nct04492488.json